The Latest Breaking News from Abiomed

When Thorsten Siess was in graduate school, he came up with the idea for a heart device that's now been used in hundreds of thousands of patients around the world.

Tighter bank lending and the Fed’s continued fight against inflation will likely push the economy into a recession this year. In this scenario, investors can look to invest in the pharma giant Johnson & Johnson (JNJ), given its financial strength, reliable dividend payments, and solid growth prospects. Read more….

Abiomed (NASDAQ:ABMD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Abiomed will report an earnings per share (EPS) of $1.09.

Abiomed (NASDAQ:ABMD) has observed the following analyst ratings within the last quarter:

Upgrades

According to Benzinga Pro data Abiomed (NASDAQ:ABMD) posted a 19.67% decrease in earnings from Q2. Sales, however, increased by 5.25% over the previous quarter to $261.18 million.

  Abiomed (NASDAQ:ABMD) reported its Q3 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

If history is any guide, there may be trouble ahead for shares of Abiomed (NASDAQ:ABMD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.